This page shows the latest risdiplam news and features for those working in and with pharma, biotech and healthcare.
Roche’s risdiplam is a closer competitor to Biogen’s drug, based on its target age range. ... It could however have a dosing advantage – risdiplam is an orally-active treatment, while Spinraza is injected into the spine.
On the other hand, risdiplam has to be taken every day while Spinraza is dosed every four months after multiple injections in an initial loading period. ... Roche is also emphasising the safety of risdiplam, saying that “no treatment related safety
s small-molecule drug risdiplam which is due to be filed before year end – the jury is out on future growth rates.
Filings are also planned for anti-IL-6 antibody satralizumab for neuromyelitis optica and risdiplam, a small-molecule drug for spinal muscular atrophy (SMA) that would compete with Biogen’s Spinraza
Severin Schwan. One of the firm's most promising late-stage pipeline projects is spinal muscular atrophy (SMA) project risdiplam, which is set to rival Biogen’s Spinraza.
Competition in SMA will further intensify with the anticipated future approval of Roche’s contender, risdiplam.
More from news
Approximately 4 fully matching, plus 13 partially matching documents found.
Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...